...
首页> 外文期刊>Journal of Ginseng Research >Effects of gut microbiota on the pharmacokinetics of protopanaxadiol ginsenosides Rd, Rg3, F2, and compound K in healthy volunteers treated orally with red ginseng
【24h】

Effects of gut microbiota on the pharmacokinetics of protopanaxadiol ginsenosides Rd, Rg3, F2, and compound K in healthy volunteers treated orally with red ginseng

机译:Gut Microbiota对原始志愿者的原子酰吡酚(RG3,F2和化合物K)对原来的术治疗志愿者的原子油动力学

获取原文

摘要

Background It is well recognized that gut microbiota is involved in the biotransformation of ginsenosides by converting the polar ginsenosides to nonpolar bioactive ginsenosides. However, the roles of the gut microbiota on the pharmacokinetics of ginsenosides in humans have not yet been fully elucidated. Methods Red ginseng (RG) or fermented red ginseng was orally administered to 34 healthy Korean volunteers, and the serum concentrations of the ginsenosides were determined using liquid chromatography–tandem mass spectrometry. In addition, the fecal ginsenoside Rd– and compound K (CK)–forming activities were measured. Then, the correlations between the pharmacokinetic profiles of the ginsenosides and the fecal ginsenoside–metabolizing activities were investigated. Results For the RG group, the area under the serum concentration–time curve values of ginsenosides Rd, F2, Rg3, and CK were 8.20?±?11.95 ng·h/mL, 4.54?±?3.70 ng·h/mL, 36.40?±?19.68 ng·h/mL, and 40.30?±?29.83 ng·h/mL, respectively. For the fermented red ginseng group, the the area under curve from zero to infinity (AUCsub∞/sub) values of ginsenosides Rd, F2, Rg3, and CK were 187.90?±?95.87 ng·h/mL, 30.24?±?41.87 ng·h/mL, 28.68?±?14.27 ng·h/mL, and 137.01?±?96.16 ng·h/mL, respectively. The fecal CK-forming activities of the healthy volunteers were generally proportional to their ginsenoside Rd–forming activities. The area under the serum concentration–time curve value of CK exhibited an obvious positive correlation (r?=?0.566, p??0.01) with the fecal CK-forming activity. Conclusion The gut microbiota may play an important role in the bioavailability of the nonpolar RG ginsenosides by affecting the biotransformation of the ginsenosides.
机译:背景技术通过将极性人参皂苷转化为非极性生物活性人参皂苷,肠道微生物群参与人参皂苷的生物转化。然而,肠道微生物植物对人类人参皂苷的药代动力学的作用尚未完全阐明。方法将红人参(RG)或发酵的红人参口服给予34个健康的韩国志愿者,使用液相色谱 - 串联质谱法测定人参皂苷的血清浓度。此外,测量粪便人参皂苷RD-和化合物K(CK)型活性。然后,研究了人参皂苷的药代动力学谱系与粪便人参皂苷代谢活性之间的相关性。 RG组的结果,血清浓度 - 时间曲线值下人参皂苷,F2,RG3和CK的面积为8.20〜±11.95 ng·H / mL,4.54?±3.70 ng·H / ml,36.40 ?±19.68 ng·h / ml,和40.30?±29.83 ng·h / ml。对于发酵的红人参组,从零到无穷大的曲线(AUC )的面积为187.90?±95.87 ng·h / ml, 30.24?±41.87 ng·h / ml,28.68?±14.27 ng·h / ml,分别为137.01?±96.16 ng·h / ml。健康志愿者的粪便CK形成活性通常与其人参皂苷RD形成活性成比例。 CK血清浓度 - 时间曲线值下的区域表现出明显的阳性相关性(R?= 0.566,p≤0.566,p≤0.01),形成粪便CK形成活性。结论通过影响人参皂苷的生物转化,肠道微生物液在非极性RG人参皂苷的生物利用度中起重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号